EUVIMEDEUVIMED entdecken
Crossref

Parotid Pleomorphic Adenoma and Apparent Diffusion Coefficient: A Novel Clinical Prediction Tool

Audrey Abend iD, Graham Keir, Karthik Krishnan, Jessica Kim, Sara Strauss, David Kutler

The Laryngoscope · 2025

DOI: 10.1002/lary.32276 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Laryngoscope, 2025. Verfasst von Audrey Abend und 5 weiteren Autor:innen. Beteiligte Einrichtung: Weill Cornell Medicine, Department of Otolaryngology-Head and Neck Surgery, New York, New York, USA. Hauptthemen laut MEDLINE: Adenoma, Pleomorphic, Parotid Neoplasms, Diffusion Magnetic Resonance Imaging. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Pleomorphic adenoma (PA) is the most common benign salivary gland tumor. MRI is a non‐invasive diagnostic tool, but its sensitivity and specificity varies. Incorporating diffusion‐weighted imaging (DWI) and quantitative apparent diffusion coefficient (ADC) assessment may enhance preoperative diagnosis. Our primary objective was to determine if including these variables in a clinical tool would enhance the diagnostic utility of MRI.

Methods

A retrospective study was conducted at Weill Cornell Medical Center, including patients with parotid masses who underwent surgical resection and preoperative MRI (2006–2022). Patient and MRI characteristics, including ADC values, were analyzed to identify predictors of PA. A logistic regression model was developed and internally validated.

Results

Among 157 patients, 86 (55%) had PA. MRI sensitivity and specificity for PA were 56% and 96%, respectively. Key predictors of PA included higher ADC values ( p < 0.001), T2 hyperintense signal ( p = 0.006), lobulated tumor contour ( p = 0.021), and absence of dumbbell shape ( p = 0.047). The final model achieved a sensitivity of 83% and specificity of 82%, with an area under the curve of 0.87. False negatives were significantly associated with lower ADC values, qualitative diffusion restriction, non‐uniform tumor enhancement pattern, and intermediate/hypointense T2 signal.

Conclusion

Qualitative MRI features combined with quantitative ADC values offer a non‐invasive, accurate approach for diagnosing PA. The proposed clinical calculator enhances preoperative planning, though external validation is warranted. Level of Evidence: 3.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenoma, PleomorphicParotid NeoplasmsDiffusion Magnetic Resonance ImagingHumansRetrospective StudiesFemaleMaleMiddle AgedAdultAgedSensitivity and SpecificityPredictive Value of TestsParotid Gland

Stichwörter der Autor:innen

ADCMRIdiagnostic modeldiffusion‐weighted imagingpleomorphic adenomasalivary gland tumor

Autor:innen und Institutionen

  • Weill Cornell Medicine, Department of Otolaryngology-Head and Neck Surgery, New York, New York, USA.
  • Department of Otolaryngology-Head and Neck Surgery, Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
  • Weill Cornell Medicine, Department of Radiology, New York, New York, USA.
  • Weill Cornell Medicine, Department of Statistics, Division of Biostatistics, New York, New York, USA.

ORCID-Profile: Audrey Abend

Zitieren

APA

Abend, A., Keir, G., Krishnan, K., Kim, J., Strauss, S., & Kutler, D. (2025). Parotid Pleomorphic Adenoma and Apparent Diffusion Coefficient: A Novel Clinical Prediction Tool. The Laryngoscope. https://doi.org/10.1002/lary.32276

Vancouver

Abend A, Keir G, Krishnan K, Kim J, Strauss S, Kutler D. Parotid Pleomorphic Adenoma and Apparent Diffusion Coefficient: A Novel Clinical Prediction Tool. The Laryngoscope. 2025. doi:10.1002/lary.32276

BibTeX
@article{Abend2025,
  author = {Abend, Audrey and Keir, Graham and Krishnan, Karthik and Kim, Jessica and Strauss, Sara and Kutler, David},
  title = {Parotid Pleomorphic Adenoma and Apparent Diffusion Coefficient: A Novel Clinical Prediction Tool},
  journal = {The Laryngoscope},
  year = {2025},
  doi = {10.1002/lary.32276}
}
Kostenlos starten →